2025 H1 -tulosraportti
Vain PDF
119 päivää sitten
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
4 249
Myynti
Määrä
23 062
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 000 | - | - |
Ylin
2,12VWAP
Alin
2,12VaihtoMäärä
0 1 000
VWAP
Ylin
2,12Alin
2,12VaihtoMäärä
0 1 000
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr, FactSet| Seuraava tapahtuma | |
|---|---|
| 2025 H2 -tulosraportti | 9.4. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 H1 -tulosraportti | 25.9.2025 | |
| 2024 H2 -tulosraportti | 9.4.2025 | |
| 2024 Q2 -tulosraportti | 30.9.2024 | |
| 2024 H1 -tulosraportti | 30.9.2024 | |
| 2023 Q4 -tulosraportti | 18.4.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 päivä sittenHere is a summary of the most important positive and challenging factors for the company right now: 🌟 The Positives (Opportunities) Clinical progress: The company recently (January 9, 2026) presented data from its Phase 2 study (ENACT) on pancreatic cancer at the ASCO Gastrointestinal Cancers Symposium. This is a critical milestone to prove that their Acoustic Cluster Therapy (ACT®) works in practice on humans. Strong partners: The collaboration with GE HealthCare, which is both an investor and a technical partner (development of specialized probes), gives the company a credibility and resource base that is rare for such small biotech companies. Proof of Concept: Earlier Phase 1 data (ACTIVATE) showed a 4-fold greater reduction in tumors treated with ACT combined with chemotherapy, compared to those who only received chemotherapy. Strategic position: In a biotech market that in 2026 shows signs of increased acquisition activity (M&A), Exact could be a candidate for larger players if Phase 2 results continue to impress. ⚠️ The Challenges (Risks) Low cash reserves: Analyses indicate that the company has less than one year of cash runway left. This means they will likely need to raise more money during 2026, which can often dilute existing shareholders. High volatility: The share price has been very unstable. Although there have been periods of strong gains, the long-term trend in recent years has been downwards. Technical signals: Technical analyses (such as moving averages and RSI) have recently shown "Sell" signals, indicating that the market is still awaiting clarity on the company's financial framework. Summary For an investor, the "crystal ball" seems to say the following: The technology appears to work, but the wallet is thin. The next major turning point will be the planned interim readout (temporary results) from the Phase 2 study in the first half of 2026. Good news here could send the stock sharply up and make it easier to secure further financing. Conclusion? Very high risk of dilution, with a hope for good readouts ahead of new financing (see above)- ·29.10.2025"The company now has money that can last until the end of 2026. If the company is to reach the top line results, which are predicted for the first half of 2027, the company needs just under 30 million kroner." Read more here: https://medwatch.no/nyheter/legemidler_biotek/article18082882.ece The article is from April 2025. The questions are whether they will get the 30 million, and at what rate? Down to 50 øre? And not least the results from the phase 2 study, which is expected in the second half of 2025.
·10.10.2025Those who are invested here probably caught the economic news where Per Hvaldai was a guest on September 25. Notice what Karl Molnes points out about ownership and finances. The largest owners have control over the entire company in practice via mechanisms that are similar to death spiral loans. The reporter asks if they don't want to treat the small shareholders more fairly, to which Hvaldai just grins away that it must be up to the board. And who is on the board? Yes, it is the largest owners and they focus exclusively on enriching themselves. That is, it pays for these big ones to push the price down as far as they can, because it means that they will be able to print up so many new shares soon that all other small ones will be zeroed out. The big ones get enormous amounts of shares at around 1 krone Similar to Circio. There it is Atlas Holding that has the opportunity to constantly print up more and more cheap shares as they manage to push the price lower. Look up what a death spiral loan is. Per Hvaldai and Amir Snappeir were the old crooks who managed to get good initial results in small trials in PCIB back in the days. There was also a complicated treatment there involving going in and lighting a small bile duct passage. Lots of devices, few patients, not something BP wants. Now they have moved to Exact, and it's the same old thing. They have already managed to get it done with nasty financing that resembles a death spiral loan, and there is a lot of stuff with devices with bubbles that are supposed to be activated in various organs by going in and stroking the cancerous areas with ultrasound. Je je
·3.10.2025Per Walday mentioned in the economic news on the 25th about a conference in Berlin that was supposed to be this weekend where new things were going to be presented, does anyone know anything about it?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 H1 -tulosraportti
Vain PDF
119 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenHere is a summary of the most important positive and challenging factors for the company right now: 🌟 The Positives (Opportunities) Clinical progress: The company recently (January 9, 2026) presented data from its Phase 2 study (ENACT) on pancreatic cancer at the ASCO Gastrointestinal Cancers Symposium. This is a critical milestone to prove that their Acoustic Cluster Therapy (ACT®) works in practice on humans. Strong partners: The collaboration with GE HealthCare, which is both an investor and a technical partner (development of specialized probes), gives the company a credibility and resource base that is rare for such small biotech companies. Proof of Concept: Earlier Phase 1 data (ACTIVATE) showed a 4-fold greater reduction in tumors treated with ACT combined with chemotherapy, compared to those who only received chemotherapy. Strategic position: In a biotech market that in 2026 shows signs of increased acquisition activity (M&A), Exact could be a candidate for larger players if Phase 2 results continue to impress. ⚠️ The Challenges (Risks) Low cash reserves: Analyses indicate that the company has less than one year of cash runway left. This means they will likely need to raise more money during 2026, which can often dilute existing shareholders. High volatility: The share price has been very unstable. Although there have been periods of strong gains, the long-term trend in recent years has been downwards. Technical signals: Technical analyses (such as moving averages and RSI) have recently shown "Sell" signals, indicating that the market is still awaiting clarity on the company's financial framework. Summary For an investor, the "crystal ball" seems to say the following: The technology appears to work, but the wallet is thin. The next major turning point will be the planned interim readout (temporary results) from the Phase 2 study in the first half of 2026. Good news here could send the stock sharply up and make it easier to secure further financing. Conclusion? Very high risk of dilution, with a hope for good readouts ahead of new financing (see above)
- ·29.10.2025"The company now has money that can last until the end of 2026. If the company is to reach the top line results, which are predicted for the first half of 2027, the company needs just under 30 million kroner." Read more here: https://medwatch.no/nyheter/legemidler_biotek/article18082882.ece The article is from April 2025. The questions are whether they will get the 30 million, and at what rate? Down to 50 øre? And not least the results from the phase 2 study, which is expected in the second half of 2025.
- ·10.10.2025Those who are invested here probably caught the economic news where Per Hvaldai was a guest on September 25. Notice what Karl Molnes points out about ownership and finances. The largest owners have control over the entire company in practice via mechanisms that are similar to death spiral loans. The reporter asks if they don't want to treat the small shareholders more fairly, to which Hvaldai just grins away that it must be up to the board. And who is on the board? Yes, it is the largest owners and they focus exclusively on enriching themselves. That is, it pays for these big ones to push the price down as far as they can, because it means that they will be able to print up so many new shares soon that all other small ones will be zeroed out. The big ones get enormous amounts of shares at around 1 krone Similar to Circio. There it is Atlas Holding that has the opportunity to constantly print up more and more cheap shares as they manage to push the price lower. Look up what a death spiral loan is. Per Hvaldai and Amir Snappeir were the old crooks who managed to get good initial results in small trials in PCIB back in the days. There was also a complicated treatment there involving going in and lighting a small bile duct passage. Lots of devices, few patients, not something BP wants. Now they have moved to Exact, and it's the same old thing. They have already managed to get it done with nasty financing that resembles a death spiral loan, and there is a lot of stuff with devices with bubbles that are supposed to be activated in various organs by going in and stroking the cancerous areas with ultrasound. Je je
- ·3.10.2025Per Walday mentioned in the economic news on the 25th about a conference in Berlin that was supposed to be this weekend where new things were going to be presented, does anyone know anything about it?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
4 249
Myynti
Määrä
23 062
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 000 | - | - |
Ylin
2,12VWAP
Alin
2,12VaihtoMäärä
0 1 000
VWAP
Ylin
2,12Alin
2,12VaihtoMäärä
0 1 000
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr, FactSet| Seuraava tapahtuma | |
|---|---|
| 2025 H2 -tulosraportti | 9.4. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 H1 -tulosraportti | 25.9.2025 | |
| 2024 H2 -tulosraportti | 9.4.2025 | |
| 2024 Q2 -tulosraportti | 30.9.2024 | |
| 2024 H1 -tulosraportti | 30.9.2024 | |
| 2023 Q4 -tulosraportti | 18.4.2024 |
2025 H1 -tulosraportti
Vain PDF
119 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr, FactSet| Seuraava tapahtuma | |
|---|---|
| 2025 H2 -tulosraportti | 9.4. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 H1 -tulosraportti | 25.9.2025 | |
| 2024 H2 -tulosraportti | 9.4.2025 | |
| 2024 Q2 -tulosraportti | 30.9.2024 | |
| 2024 H1 -tulosraportti | 30.9.2024 | |
| 2023 Q4 -tulosraportti | 18.4.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenHere is a summary of the most important positive and challenging factors for the company right now: 🌟 The Positives (Opportunities) Clinical progress: The company recently (January 9, 2026) presented data from its Phase 2 study (ENACT) on pancreatic cancer at the ASCO Gastrointestinal Cancers Symposium. This is a critical milestone to prove that their Acoustic Cluster Therapy (ACT®) works in practice on humans. Strong partners: The collaboration with GE HealthCare, which is both an investor and a technical partner (development of specialized probes), gives the company a credibility and resource base that is rare for such small biotech companies. Proof of Concept: Earlier Phase 1 data (ACTIVATE) showed a 4-fold greater reduction in tumors treated with ACT combined with chemotherapy, compared to those who only received chemotherapy. Strategic position: In a biotech market that in 2026 shows signs of increased acquisition activity (M&A), Exact could be a candidate for larger players if Phase 2 results continue to impress. ⚠️ The Challenges (Risks) Low cash reserves: Analyses indicate that the company has less than one year of cash runway left. This means they will likely need to raise more money during 2026, which can often dilute existing shareholders. High volatility: The share price has been very unstable. Although there have been periods of strong gains, the long-term trend in recent years has been downwards. Technical signals: Technical analyses (such as moving averages and RSI) have recently shown "Sell" signals, indicating that the market is still awaiting clarity on the company's financial framework. Summary For an investor, the "crystal ball" seems to say the following: The technology appears to work, but the wallet is thin. The next major turning point will be the planned interim readout (temporary results) from the Phase 2 study in the first half of 2026. Good news here could send the stock sharply up and make it easier to secure further financing. Conclusion? Very high risk of dilution, with a hope for good readouts ahead of new financing (see above)
- ·29.10.2025"The company now has money that can last until the end of 2026. If the company is to reach the top line results, which are predicted for the first half of 2027, the company needs just under 30 million kroner." Read more here: https://medwatch.no/nyheter/legemidler_biotek/article18082882.ece The article is from April 2025. The questions are whether they will get the 30 million, and at what rate? Down to 50 øre? And not least the results from the phase 2 study, which is expected in the second half of 2025.
- ·10.10.2025Those who are invested here probably caught the economic news where Per Hvaldai was a guest on September 25. Notice what Karl Molnes points out about ownership and finances. The largest owners have control over the entire company in practice via mechanisms that are similar to death spiral loans. The reporter asks if they don't want to treat the small shareholders more fairly, to which Hvaldai just grins away that it must be up to the board. And who is on the board? Yes, it is the largest owners and they focus exclusively on enriching themselves. That is, it pays for these big ones to push the price down as far as they can, because it means that they will be able to print up so many new shares soon that all other small ones will be zeroed out. The big ones get enormous amounts of shares at around 1 krone Similar to Circio. There it is Atlas Holding that has the opportunity to constantly print up more and more cheap shares as they manage to push the price lower. Look up what a death spiral loan is. Per Hvaldai and Amir Snappeir were the old crooks who managed to get good initial results in small trials in PCIB back in the days. There was also a complicated treatment there involving going in and lighting a small bile duct passage. Lots of devices, few patients, not something BP wants. Now they have moved to Exact, and it's the same old thing. They have already managed to get it done with nasty financing that resembles a death spiral loan, and there is a lot of stuff with devices with bubbles that are supposed to be activated in various organs by going in and stroking the cancerous areas with ultrasound. Je je
- ·3.10.2025Per Walday mentioned in the economic news on the 25th about a conference in Berlin that was supposed to be this weekend where new things were going to be presented, does anyone know anything about it?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
4 249
Myynti
Määrä
23 062
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 000 | - | - |
Ylin
2,12VWAP
Alin
2,12VaihtoMäärä
0 1 000
VWAP
Ylin
2,12Alin
2,12VaihtoMäärä
0 1 000
Välittäjätilasto
Dataa ei löytynyt